^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | Adstiladrin (nadofaragene firadenovec-vncg) (IFNα stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer
Published date:
12/16/2022
Excerpt:
...U.S. Food and Drug Administration approved Adstiladrin (nadofaragene firadenovec-vncg), a non-replicating (cannot multiply in human cells) adenoviral vector based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
